Oncternal Therapeutics, Inc. (ONCT) News

Oncternal Therapeutics, Inc. (ONCT): $1.50

0.04 (+2.74%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add ONCT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#105 of 362

in industry

Filter ONCT News Items

ONCT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest ONCT News From Around the Web

Below are the latest news stories about ONCTERNAL THERAPEUTICS INC that investors may wish to consider to help them evaluate ONCT as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!

William White on InvestorPlace | December 12, 2023

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […]

Yahoo | November 11, 2023

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

The first patient was dosed in our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitorsAdditional patients were treated in our ongoing Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients that have failed prior CD19 CAR

Yahoo | November 9, 2023

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets close on Thursday, November 9, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s third quarter financial results. The li

Yahoo | November 2, 2023

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer

Yahoo | October 26, 2023

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB). Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal’s next steps in the clinical development of its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-5

Yahoo | October 25, 2023

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor. “The dosing of the first patient with ONCT-534 is an important milestone for patients suffering from advanced prostate cancer who have

Yahoo | October 5, 2023

We're A Little Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Yahoo | September 17, 2023

Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate Cancer SAB is comprised of distinguished academic and industry leaders in the prostate cancer field, which will advise Oncternal as it develops its novel dual-acting androgen receptor inhibitor (DAARI), ONCT

Yahoo | September 7, 2023

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor signaling inhibitorsDosed the first patient in our Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphomaCash runway extended into 2025, with $45.5 million in cash, cash equivalents and short

Yahoo | August 10, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!